| Name | Almitrine Bismesylate + Raubasine |
| Classes |
Central Nervous System Agent Respiratory Agent |
| Diseases |
Buzzing CNS Disorder Dizziness Hearing Loss Neurological Damage Stroke Visual Disorder |
Bangla
EnglishAlmitrine Bismesylate + Raubasine
This combination medication contains Almitrine Bismesylate, a respiratory stimulant, and Raubasine, a vasodilator with potential cerebrovascular effects. Almitrine Bismesylate enhances ventilation-perfusion matching in the lungs, increasing oxygenation, while Raubasine contributes to cerebral blood flow regulation. The synergistic action of both components aims to improve oxygen delivery and utilization in various conditions.
This drug is prescribed for minimizing neurological damage and expediting recovery following cerebral stroke, addressing minor age-related neurological disorders, certain visual issues linked to circulation, and specific inner ear disorders associated with circulation, including hearing loss, dizziness, and ringing in the ear.
Take one tablet once or twice a day, separated by several hours, with a maximum of two tablets per day. Alternatively, follow the instructions provided by a licensed medical practitioner.
The following side effects may occur-
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Flushing
- Palpitations
- Hypertension
- Respiratory Distress: Monitor patients for signs of respiratory distress, especially in those with pre-existing respiratory conditions. Adjust the dosage or discontinue treatment if respiratory distress occurs.
- Cardiovascular Effects: Caution is advised in patients with cardiovascular conditions, as Raubasine may have cardiovascular effects. Monitor blood pressure, pulse, and ECG regularly.
- Hepatic Impairment: Use with caution in patients with hepatic impairment, as the metabolism of Almitrine Bismesylate may be affected. Adjust dosage based on hepatic function.
- Renal Impairment: Adjust dosage in patients with renal impairment, as both components may undergo renal elimination. Regularly assess renal function.
- Pregnancy and Lactation: The safety of Almitrine Bismesylate + Raubasine during pregnancy and lactation has not been established. Use in pregnant or breastfeeding women only if the potential benefits justify the potential risks.
Contraindication
Almitrine Bismesylate + Raubasine is contraindicated in Patients with a known hypersensitivity to Almitrine Bismesylate, Raubasine, or any component of the formulation.
- Pregnancy, especially during the first trimester.
- Patients with severe hepatic impairment.
- Patients with acute respiratory failure or severe pulmonary hypertension.
- Concurrent use with other respiratory stimulants.
None known.
Almitrine Bismesylate + Raubasine is contraindicated in-
- Pregnancy, especially during the first trimester.
- Patients with severe hepatic impairment.
